$EW

Zovighian Bernard J sold $245K of EW (indirect holdings)

Zovighian Bernard J (CEO) sold 2,921 indirectly-held shares of Edwards Lifesciences Corp (EW) at $83.93 ($0.25M total) on 2026-07-27.

Original reporting
SEC EDGAR · Zovighian Bernard J
Published Jul 27, 2026, 10:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 27, 2026, 11:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EW
Neutral
medium confidence
Mentioned
$EW
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EWNeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale of 2,921 shares at $83.9342 on 2026-07-27, totaling $245,134.12, with holdings after sale of 8,916 shares and no pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not change the company’s fundamentals.

03

What to watch

The filing notes indirect holdings and post-transaction share count, but does not disclose the broader trading history, tax events, or whether other insiders executed offsetting buys.

Relevance 4/10Novelty 3/10Timing: SEC Form 4 filed today, 2026-07-27 (after-hours filing timestamp).

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Edwards Lifesciences (EW).

Company-level read

Ticker impact

$EWNeutralMedium confidence
Context

Edwards Lifesciences CEO Zovighian sold 2,921 shares in an open-market transaction for about $245K, disclosed via Form 4 today.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing provides transaction size, price, and post-sale holdings, but no new operational, financial, or regulatory information. Insider sales can be interpreted both ways, and the disclosed value is modest relative to typical market capitalization.

Market effects

No direct sector read-through; this is an issuer-specific insider transaction.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification or personal liquidity needs, and the absence of a 10b5-1 plan does not necessarily imply negative expectations without additional context.

Key entities

  • Edwards Lifesciences Corp

    US-listed medical device company subject of the Form 4 insider sale disclosure.

  • Zovighian Bernard J

    CEO and officer/director who sold shares via an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EWMedAI 8/10

CMS Expands Medicare Coverage for Edwards TAVR

CMS expanded Medicare coverage for Edwards Lifesciences' TAVR procedure to asymptomatic severe aortic stenosis patients. The company reiterated its 10-11% sales growth guidance. Shares (EW) fell 2.7% to $84.37. Analysts see upside, with Jefferies raising its price target to $105.

$EWMedAI 8/10

BD Taps Edwards Lifesciences Veteran Gary Sorsher to Lead Global Quality

BD appointed Gary Sorsher, former Chief Quality Officer at Edwards Lifesciences, as its new Executive Vice President and Chief Quality Officer. Sorsher brings over 30 years of experience in quality roles. The move follows Jeffrey Silvestri's planned retirement. BD's CEO highlighted Sorsher's global experience and focus on continuous improvement. Edwards Lifesciences received FDA clearance for its Ecliptis left atrial appendage exclusion system, entering the surgical stroke-prevention market. BD

$EWMed

Edwards Lifesciences, Medtronic score CMS win over TAVR

Edwards Lifesciences (EW) and Medtronic (MDT) welcomed CMS's decision to expand Medicare coverage for TAVR to asymptomatic severe aortic stenosis patients, citing improved access and streamlined care. EW shares fell 2% to $84.31, MDT dropped 1% to $90.70. CMS's decision was based on EW's Early TAVR trial data, showing lower adverse outcomes for prompt TAVR. Analysts view the decision as positive for TAVR growth.

$EWHigh

CMS TAVR changes, a boon for Edwards

The CMS has expanded Medicare coverage for TAVR procedures to include asymptomatic severe aortic stenosis patients. Edwards Lifesciences Corp. has advocated for this change, which may benefit the company.

$EWHighAI 8/10

Edwards Lifesciences stock price target maintained at $85 by Canaccord

Canaccord maintained a Hold rating and $85 price target for Edwards Lifesciences (EW) after a Medicare coverage decision on TAVR procedures. The stock trades at $86.77, above the target but below consensus. CMS finalized changes Edwards requested, expanding coverage for asymptomatic severe aortic stenosis. Edwards confirmed its 2026 financial guidance, expecting long-term benefits. Analysts have mixed price targets, ranging from $84 to $110. The company reported strong Q2 results, with sales of

$EWHighAI 8/10

Stifel sees CMS TAVR coverage update as positive for Edwards

CMS finalized TAVR coverage, benefiting Edwards Lifesciences due to its market leadership. Stifel analysts view the update positively, supporting Edwards' revenue growth outlook. TAVR represents 75% of Edwards' revenues and 5.5% of Medtronic's. CMS also initiated coverage analysis for devices treating aortic regurgitation, including Edwards' J-Valve.